About Doxall

Doxall is the first major development by our parent company Wintermute Biomedical in our fight against drug resistant microorganisms, it’s also one of the biggest scientific advances in sanitising since the 1950s. A decade of research went into the creation of Doxall’s patented science, which has unlocked the power of a safe, natural fatty acid called Capric acid. Our studies have found that Doxall: 

  • Kills 99.9% of harmful germs and bacteria on hands and surfaces 
  • Doesn’t require pre-cleaning to reach full effectiveness, unlike other disinfectants 
  • Is gentle and nurturing on skin and surfaces when used as directed 

 We are continuing to conduct research on all the possibilities Doxall presents, including whether it can prevent the development of drug resistant microorganisms. What we already know is this: When applied to surfaces or hands, Doxall creates a safe and natural bioactive surface that kills 99.9% of germs and continues to be effective for some time after it has dried. 

 Doxall is showing great potential in other important industries with unwanted microbial growth, such as poultry farms & piggeries; recycling projects; crop protection; and waste and pollution. We are partnering with innovative companies, such as Ecochem (www.ecochem.com.au), looking for applications that provide a brighter, more sustainable future.  If you would like to partner with us, feel free to contact us. 

 Have questions about Doxall? Learn more by exploring our solutions page and FAQ and feel free to contact us if you want to purchase our products or discuss our research 

The Science Behind Doxall 

Doxall’s main component is Capric acid: a medium chain fatty acid that has recognised antimicrobial activity. Despite this known antimicrobial activity, fatty acids have not traditionally been used in sanitisers as they aren’t water-soluble, so they wouldn’t be an effective disinfectant when applied to hands and surfaces. This is the heart of Doxall’s innovation: we found a way to make Capric acid water-soluble. 

 By mixing Capric acid with an amino acid, we’ve made a fatty acid water-soluble without removing any of its anti-microbial power or introducing organic solvents like ethanol to the solution. How does it work? Well, the positive charge from the arginine interacts with the negative charge on the carboxyl group of the fatty acid to allow solubility in water. 

 The result is a very effective disinfectant made entirely from naturally occurring ingredients! 

The Mission Behind Doxall

Driven by our research ethos to contribute to health and well-being, Doxall was developed as part of Wintermute Biomedical’s mission to fight against dangerous antibiotic resistant microorganisms.   

Antimicrobial Resistance, or AMR, is the term used when dangerous microorganisms become resistant to traditional antibiotic treatments. Not only can bacteria develop resistance to treatment, they can also pass on the resistance gene to other bacteria, even bacteria of different species. Microorganisms that that have developed resistance are colloquially called "superbugs". 

Each year more than 700,000 people die from drug-resistant infections, including infections acquired while in hospital. On current projections, the toll will increase to a staggering 10 million deaths a year by 2050. That would be the equivalent of 2 Covid pandemics every year. This is why the World Health Organisation has declared: AMR is one of the top 10 global public health threats facing humanity.  

Without solutions we face a nightmare future scenario where basic infections may again become deadly. Routine medical procedures will carry the possibility of infection with a life-threatening superbug.    

At Doxall, helping solve this problem drives us. Your choice of Doxall supports our passion to fight dangerous antibiotic resistant organisms. We value your support.   

The People Behind Doxall

Dr Tony Peacock – CEO 
Tony has been Chief Executive of the Cooperative Research Centres Association for 10 years. He is a Fellow of both the Australian Academy of Technology and Engineering and the Australian Institute of Company Directors, and was the 2014 Monash University Churchill Fellow studying university-business relationships. Find Tony on LinkedIn. 

Dr Thomas Rau – Co-Founder & Chief Scientific Officer 
Tom is a Doxall co-founder and inventor, with over 20 years' experience in scientific research. He specialises in neuroscience and medical microbiology, with a particular focus on multidrug-resistant bacteria. Find Tom on LinkedIn. 

Carolyn Riska – Operations Manager 
Carolyn has a Science Degree consolidated by 15 years in varied commercial roles within the pharmaceutical industry. She spent 10 years building a highly successful private mobility aids equipment business which was acquired in 2019 by a private equity investor. Carolyn brings a strength of operational and commercial expertise. Find Carolyn on LinkedIn.

Dr Alyce Mayfosh – Scientific Project Manager 
Alyce obtained her PhD from the La Trobe Institute for Molecular Science, La Trobe University. She specialises in cancer immunology, molecular biology and cell biology. Alyce is manager of the scientific program in relation to disinfectants and shingles. Find Alyce on LinkedIn.